compound, pharmaceutical composition, method for inhibiting double leucine zipper kinase, method for treating a double leucine zipper kinase mediated disease and method for obtaining an effect on a patient
GANG LIU,JAMES RAY,JASON CROSS,KANG LE,MICHAEL J. SOTH,PHILIP JONES
申请号：
BR112019004243
公开号：
BR112019004243A2
申请日:
2017.08.28
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
Disclosed herein are compounds which inhibit the activity of double leucine zipper kinase (dlk) kinase (map3k12), pharmaceutical compositions and methods for treating dlk-mediated diseases, such as neurological disorders resulting from traumatic injury to the neurons of the central nervous system and peripheral nervous system (eg, stroke, traumatic brain injury, spinal cord injury), or resulting from a chronic neurodegenerative disorder (eg alzheimer's disease, frontotemporal dementia, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, spinocerebellar degeneration, progressive supranuclear palsy, lewy body disease, kennedy disease and other related conditions), neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy and related disorders) and cognitive disorders caused by pharmacological intervention (eg, chemotherapy-induced cognitive impairment, also known as chemotherapy fog).são revelados no presente documento compostos que inibem a atividade de quinase da quinase de zíper de leucina dupla (dlk) (map3k12), composições farmacêuticas e métodos para tratamento de doenças mediadas por dlk, tal como doenças neurológicas que resultam de lesão traumática nos neurônios do sistema nervoso central e sistema nervoso periférico (por exemplo, derrame, lesão cerebral traumática, lesão na medula espinhal), ou que resultam de uma afecção neurodegenerativa crônica (por exemplo, mal de alzheimer, demência frontotemporal, mal de parkinson, doença de huntington, esclerose lateral amiotrófica, degeneração espinocerebelar, paralisia supranuclear progressiva, doença com corpos de lewy, doença de kennedy e outras afecções relacionadas), de neuropatias que resultam de dano neurológico (neuropatia periférica induzida por quimioterapia, neuropatia diabética e afecções relacionadas) e de distúrbios cognitivos provocados por intervenção farmacológica (por exemplo, distúrbio cognitivo induzido por quimioterapia,
